Positioning of bispecific antibody therapy in conjunction with CAR T cells to treat relapsed/refractory DLBCL is an area of active investigation. Bispecifics are off the shelf and easier to administer. They have high efficiency and durability, even as monotherapies. Like CAR T cells, bispecifics als...

The practical considerations for incorporating bispecific antibodies into the treatment of relapsed DLBCL is the awareness of the potential side effects, although less than CAR T-cell therapy, in regards to the risk of cytokine release syndrome (CRS) and immune-effector cell associated neurotoxicity...